WHO is committed to updating its policy guidance whenever relevant new information has been obtained through the use of the vaccine in populations around the world and new results from clinical research.
Accordingly, new data continues to regularly emerge from ongoing clinical trials and monitoring on the AstraZeneca COVID-19 Vaccine and other vaccines. On the basis of this additional evidence, the Strategic Advisory Group of Experts (SAGE) on Immunization has updated its interim guidance on the use of the AstraZeneca vaccines against COVID-19 that are produced by different manufacturers (Astra Zeneca-Vaxzevria, Serum Institute India SII Covishield, and SK Bioscience).
WHO continues to support the conclusion that the benefits of these vaccines outweigh the risks. Pursuant to the latest data, further clarification of precautions and types of risk (ie. Thrombosis with Thrombocytopenia Syndrome) has been added. More data have been obtained on the effectiveness of the vaccines in different population groups, such as older adults, making the evidence base more robust. Clarifications and specifications have been added as to the vaccination of specific population groups (pregnant and lactating women, person with previous SARS-CoV2 infection and others).
The changes to these Interim Recommendations apply to multiple sections of the document. The updated version is available here.
The SAGE Working Group on COVID-19 Vaccines will continue to evaluate available data and modify the guidance as required.